GSTM1 and colorectal carcinoma: The increasing f-Hb in groups, which strongly suggests an increase in CRC mortality, can be used to stratify the underlying population into different risk groups to re-align the interscreening interval based on different f-Hb levels at baseline for reducing false-negative and false-positive results simultaneously.